dalelynnsims
07-25-05, 08:30 PM
From: http://www.in-pharmatechnologist.com/news/news-ng.asp?n=61500-drug-treatment-mimics
UK company Diurnal has received orphan product designation from the European Commission for a novel treatment that uses a drug delivery technology to match the body’s circadian rhythms.
The designation is for a modified release hydrocortisone tablet for the treatment of congenital adrenal hyperplasia, a genetic defect of the adrenal glands. The product is being developed by Phoqus Pharmaceuticals, a drug delivery company also based in the UK. Phoqus recently licensed a Diurnal patent that relates to delayed and sustained release therapy, and will apply its proprietary Qtrol technology to the new product.
See url for complete article
UK company Diurnal has received orphan product designation from the European Commission for a novel treatment that uses a drug delivery technology to match the body’s circadian rhythms.
The designation is for a modified release hydrocortisone tablet for the treatment of congenital adrenal hyperplasia, a genetic defect of the adrenal glands. The product is being developed by Phoqus Pharmaceuticals, a drug delivery company also based in the UK. Phoqus recently licensed a Diurnal patent that relates to delayed and sustained release therapy, and will apply its proprietary Qtrol technology to the new product.
See url for complete article